{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T10:08:13Z","timestamp":1777716493186,"version":"3.51.4"},"reference-count":18,"publisher":"IMR Press","issue":"4","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br. J. Hosp. Med. (Lond)"],"abstract":"<jats:p>Aims\/Background: The incidence of hyperuricemia is increasing globally, and febuxostat is a commonly used therapeutic agent. Investigating the relationship between febuxostat therapy and cardiovascular events in patients with hyperuricemia is of significant clinical value. This study aimed to construct a cardiovascular event prediction model for patients with hyperuricemia treated with febuxostat and to analyze factors associated with cardiovascular events, to provide a basis for clinical risk management. Methods: This single-center retrospective cohort study enrolled patients with hyperuricemia who were treated with febuxostat at Quzhou Municipal People\u2019s Hospital between January 2021 and January 2024 and were followed up at 3, 6, and 12 months after treatment. Baseline information, including age, body mass index, and medical history, was collected. Univariate and multivariate analyses were performed using binary logistic regression to identify influencing and predictive factors, and a cardiovascular event risk prediction model was established. The predictive performance and clinical applicability of the model were evaluated using nomograms, receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Results: A total of 700 patients with hyperuricemia receiving febuxostat were included, and the incidence of cardiovascular events during follow-up was 19.0%. Multivariate logistic regression analysis identified age (odds ratio [OR] = 1.05), prior hypertension (OR = 5.10), and body mass index (BMI, OR = 1.22) as independent predictors of cardiovascular events. Based on these variables, the established prediction model demonstrated good discriminatory ability, with a high area under the curve (AUC). The AUC of the nomogram model was 0.80 (0.74\u20130.85) in the training set and 0.78 (0.69\u20130.87) in the validation set. The calibration curve showed good agreement (Hosmer-Lemeshow test, p &gt; 0.05). Decision curve analysis indicated a significant net clinical benefit. Conclusion: The cardiovascular event prediction model developed in this study demonstrates good predictive performance and may serve as a useful clinical tool for cardiovascular risk assessment in patients with hyperuricemia. Age, BMI, and prior hypertension are important independent risk factors for cardiovascular events in patients with hyperuricemia. Future multicenter, long-term prospective studies are warranted to further validate the generalizability of this model and the cardiovascular safety of febuxostat treatment.<\/jats:p>","DOI":"10.31083\/bjhm52969","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:17:23Z","timestamp":1777457843000},"source":"Crossref","is-referenced-by-count":0,"title":["Influencing Factors and a Predictive Model for Cardiovascular Events in Patients With Hyperuricemia Treated With Febuxostat"],"prefix":"10.31083","volume":"87","author":[{"given":"Xiaojun","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Quzhou Municipal People\u2019s Hospital, 324000 Quzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqun","family":"Chen","sequence":"additional","affiliation":[{"name":"Wound Dressing Clinic, Quzhou Municipal People\u2019s Hospital, 324000 Quzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxian","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nursing, Quzhou Municipal People\u2019s Hospital, 324000 Quzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Urology, Quzhou Municipal People\u2019s Hospital, 324000 Quzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7789-2018","authenticated-orcid":true,"given":"Yunxian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Quzhou Municipal People\u2019s Hospital, 324000 Quzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Zhang S, Zhang Y, Lin S, Zhang S, Qiu M. Hyperuricemia as a possible risk factor for abnormal lipid metabolism in the Chinese population: a cross-sectional study. Annals of Palliative Medicine. 2021; 10: 11454\u201311463.","DOI":"10.21037\/apm-21-2734"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Zhang Q, Li H, Xing D, Lin J. Global research trends in hyperuricemia: a bibliometric and visualized study. Modern Rheumatology. 2022; 32: 619\u2013625.","DOI":"10.1093\/mr\/roab031"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Vareldzis R, Perez A, Reisin E. Hyperuricemia: An Intriguing Connection to Metabolic Syndrome, Diabetes, Kidney Disease, and Hypertension. Current Hypertension Reports. 2024; 26: 237\u2013245.","DOI":"10.1007\/s11906-024-01295-3"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Lee TS, Lu TM, Chen CH, Guo BC, Hsu CP. Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine\/dimethylarginine dimethylaminotransferase 2 pathway. Redox Biology. 2021; 46: 102108.","DOI":"10.1016\/j.redox.2021.102108"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Yang XH, Zhang BL, Cheng Y, Fu SK, Jin HM. Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials. Annals of Medicine. 2024; 56: 2332956.","DOI":"10.1080\/07853890.2024.2332956"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Shin A, Choi SR, Han M, Ha YJ, Lee YJ, Lee EB, et al. Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat. Seminars in Arthritis and Rheumatism. 2022; 56: 152080.","DOI":"10.1016\/j.semarthrit.2022.152080"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Bai Y, Wu B, Gou L, Fang Z, Xu T, Zhang T, et al. Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System. Journal of Clinical Medicine. 2023; 12: 6089.","DOI":"10.3390\/jcm12186089"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. The New England Journal of Medicine. 2018; 378: 1200\u20131210.","DOI":"10.1056\/NEJMoa1710895"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Guan X, Zhang S, Liu J, Wu F, Zhou L, Liu Y, et al. Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis. Frontiers in Pharmacology. 2022; 13: 998441.","DOI":"10.3389\/fphar.2022.998441"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Chrysant SG. Association of hyperuricemia with cardiovascular diseases: current evidence. Hospital Practice (1995). 2023; 51: 54\u201363.","DOI":"10.1080\/21548331.2023.2173413"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Zheng L, Zhu Y, Ma Y, Zhang H, Zhao H, Zhang Y, et al. Relationship between hyperuricemia and the risk of cardiovascular events and chronic kidney disease in both the general population and hypertensive patients: A systematic review and meta-analysis. International Journal of Cardiology. 2024; 399: 131779.","DOI":"10.1016\/j.ijcard.2024.131779"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Pacinella G, Ciaccio AM, Tuttolomondo A. Endothelial Dysfunction and Chronic Inflammation: The Cornerstones of Vascular Alterations in Age-Related Diseases. International Journal of Molecular Sciences. 2022; 23: 15722.","DOI":"10.3390\/ijms232415722"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Wang C, Qin P, Liu Y, Wang L, Xu S, Chen H, et al. Association between hyperuricemia and hypertension and the mediatory role of obesity: a large cohort study in China. Revista Da Associacao Medica Brasileira (1992). 2023; 69: e20220241.","DOI":"10.1590\/1806-9282.20220241"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Zhou Z, Li K, Li X, Luan R, Zhou R. Independent and joint associations of body mass index, waist circumference, waist-height ratio and their changes with risks of hyperuricemia in middle-aged and older Chinese individuals: a population-based nationwide cohort study. Nutrition & Metabolism. 2021; 18: 62.","DOI":"10.1186\/s12986-021-00590-z"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Tian X, Chen S, Wang P, Xu Q, Zhang Y, Zhang X, et al. Temporal relationship between hyperuricemia and hypertension and its impact on future risk of cardiovascular disease. European Journal of Internal Medicine. 2023; 111: 82\u201389.","DOI":"10.1016\/j.ejim.2023.02.023"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Kuwabara M, Kodama T, Ae R, Kanbay M, Andres-Hernando A, Borghi C, et al. Update in uric acid, hypertension, and cardiovascular diseases. Hypertension Research. 2023; 46: 1714\u20131726.","DOI":"10.1038\/s41440-023-01273-3"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Liu XY, Wu QY, Chen ZH, Yan GY, Lu Y, Dai HJ, et al. Elevated triglyceride to high-density lipoprotein cholesterol (TG\/HDL-C) ratio increased risk of hyperuricemia: a 4-year cohort study in China. Endocrine. 2020; 68: 71\u201380.","DOI":"10.1007\/s12020-019-02176-5"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Wang M, Zhang Y, Zhang M, Li H, Wen C, Zhao T, et al. The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis. Annals of Palliative Medicine. 2021; 10: 10327\u201310337.","DOI":"10.21037\/apm-21-1564"}],"container-title":["British Journal of Hospital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/BJHM\/87\/4\/10.31083\/BJHM52969","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:18:35Z","timestamp":1777457915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/BJHM\/87\/4\/10.31083\/BJHM52969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1750-8460(26)02619-0"],"URL":"https:\/\/doi.org\/10.31083\/bjhm52969","relation":{},"ISSN":["1750-8460","1759-7390"],"issn-type":[{"value":"1750-8460","type":"print"},{"value":"1759-7390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"article-number":"52969"}}